Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The medication consists of the humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.. It has been reported that an ADC with a DAR of 8 is less effective in vivo than one with a DAR of 4, 23 which has led to the norm of targeting a DAR of 4 for an ADC. However, recent findings suggest that by reducing the hydrophobicity of the ADC, the ADC with a DAR of 8 performs much better in vivo 19 and is a feasible alternative.. on DAR, conjugation sites, and physical stability. Off-Bead samples were prepared through the Off-Bead samples were prepared through the reaction of trastuzumab with SMCC-DM1 for 2 h, followed by a one-hour incubation with glycine to. Antibody drug conjugates (ADCs) have emerged as an important pharmaceutical class of drugs designed to harness the specificity of antibodies with the potency of small molecule therapeutics. The three main components of ADCs are the antibody, the linker, and the payload; the majority of early work. . .